{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T07:51:57Z","timestamp":1687938717894},"reference-count":41,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.3892\/ijo.2016.3765","type":"journal-article","created":{"date-parts":[[2016,11,10]],"date-time":"2016-11-10T09:29:53Z","timestamp":1478770193000},"page":"2411-2420","source":"Crossref","is-referenced-by-count":3,"title":["SORORIN and PLK1 as potential therapeutic targets in malignant pleural mesothelioma"],"prefix":"10.3892","volume":"49","author":[{"given":"Tatsuya","family":"Kato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiyoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Licun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahn Jin","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironobu","family":"Wada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsin-Pei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Ujiie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhito","family":"Kaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Kano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Matsuge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromitsu","family":"Domen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Kanno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Hatanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanako C.","family":"Hatanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kichizo","family":"Kaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiro","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Matsuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"De Perrot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Yasufuku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2016,11,10]]},"reference":[{"key":"key20180107190419_b1-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11864-008-0067-z","article-title":"Mesothelioma epidemiology, carcinogenesis, and pathogenesis","volume":"9","author":"Yang","year":"2008","journal-title":"Curr Treat Options Oncol"},{"key":"key20180107190419_b2-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/sonc.2002.30227","article-title":"The pathogenesis of mesothelioma","volume":"29","author":"Carbone","year":"2002","journal-title":"Semin Oncol"},{"key":"key20180107190419_b3-ijo-49-06-2411","volume-title":"WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart","author":"Travis","year":"2015","edition":"4th edition"},{"key":"key20180107190419_b4-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1056\/NEJMra050152","article-title":"Advances in malignant mesothelioma","volume":"353","author":"Robinson","year":"2005","journal-title":"N Engl J Med"},{"key":"key20180107190419_b5-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","article-title":"Malignant mesothelioma","volume":"366","author":"Robinson","year":"2005","journal-title":"Lancet"},{"key":"key20180107190419_b6-ijo-49-06-2411","first-page":"356","article-title":"Asbestos-related diseases of the lungs and pleura: Uses, trends and management over the last century","volume":"11","author":"Becklake","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"key":"key20180107190419_b7-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"key20180107190419_b8-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1586\/era.09.2","article-title":"Future developments in the management of malignant pleural mesothelioma","volume":"9","author":"Zucali","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"key":"key20180107190419_b9-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/JTO.0000000000000078","article-title":"A feasibility study evaluating Surgery for Mesothelioma After Radiation Therapy: The \u2018SMART\u2019 approach for resectable malignant pleural mesothelioma","volume":"9","author":"Cho","year":"2014","journal-title":"J Thorac Oncol"},{"key":"key20180107190419_b10-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.lungcan.2015.11.018","article-title":"Overexpression of KIF23 predicts clinical outcome in primary lung cancer patients","volume":"92","author":"Kato","year":"2016","journal-title":"Lung Cancer"},{"key":"key20180107190419_b11-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3892\/ijo.2016.3566","article-title":"Kinesin family members KIF11 and KIF23 as potential therapeutic targets in malignant pleural mesothelioma","volume":"49","author":"Kato","year":"2016","journal-title":"Int J Oncol"},{"key":"key20180107190419_b12-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"41826","DOI":"10.1074\/jbc.M111.305888","article-title":"Interaction of Sororin protein with polo-like kinase 1 mediates resolution of chromosomal arm cohesion","volume":"286","author":"Zhang","year":"2011","journal-title":"J Biol Chem"},{"key":"key20180107190419_b13-ijo-49-06-2411","volume-title":"TNM Classification of Malignant Tumours","author":"Union for International Cancer Control (UICC)","year":"2009","edition":"7th edition"},{"key":"key20180107190419_b14-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1746-1596-7-42","article-title":"Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring","volume":"7","author":"Rizzardi","year":"2012","journal-title":"Diagn Pathol"},{"key":"key20180107190419_b15-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.lungcan.2008.03.026","article-title":"Detection of tumor-specific autoantibodies in sera of patients with lung cancer","volume":"62","author":"Nagashio","year":"2008","journal-title":"Lung Cancer"},{"key":"key20180107190419_b16-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.lungcan.2009.09.015","article-title":"Expression of RACK1 is a novel biomarker in pulmonary adenocarcinomas","volume":"69","author":"Nagashio","year":"2010","journal-title":"Lung Cancer"},{"key":"key20180107190419_b17-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.canlet.2010.02.008","article-title":"A combination of a DNA-chimera siRNA against PLK-1 and zoledronic acid suppresses the growth of malignant mesothelioma cells in vitro","volume":"294","author":"Kawata","year":"2010","journal-title":"Cancer Lett"},{"key":"key20180107190419_b18-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/bjc.2013.731","article-title":"An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma","volume":"110","author":"Linton","year":"2014","journal-title":"Br J Cancer"},{"key":"key20180107190419_b19-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.molcel.2005.03.017","article-title":"Sororin, a substrate of the anaphase-promoting complex, is required for sister chromatid cohesion in vertebrates","volume":"18","author":"Rankin","year":"2005","journal-title":"Mol Cell"},{"key":"key20180107190419_b20-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.cub.2007.02.029","article-title":"Sororin is required for stable binding of cohesin to chromatin and for sister chromatid cohesion in interphase","volume":"17","author":"Schmitz","year":"2007","journal-title":"Curr Biol"},{"key":"key20180107190419_b21-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.15252\/embj.201489988","article-title":"Splicing together sister chromatids","volume":"33","author":"Valc\u00e1rcel","year":"2014","journal-title":"EMBO J"},{"key":"key20180107190419_b22-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.4161\/cc.20241","article-title":"Sororin is a master regulator of sister chromatid cohesion and separation","volume":"11","author":"Zhang","year":"2012","journal-title":"Cell Cycle"},{"key":"key20180107190419_b23-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"5337","DOI":"10.1158\/0008-5472.CAN-09-4372","article-title":"Phosphorylation and activation of cell division cycle associated 5 by mitogen-activated protein kinase play a crucial role in human lung carcinogenesis","volume":"70","author":"Nguyen","year":"2010","journal-title":"Cancer Res"},{"key":"key20180107190419_b24-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nrd3823","article-title":"The spliceosome as a target of novel antitumour drugs","volume":"11","author":"Bonnal","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"key20180107190419_b25-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.cell.2009.02.011","article-title":"RNA and disease","volume":"136","author":"Cooper","year":"2009","journal-title":"Cell"},{"key":"key20180107190419_b26-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nrc3743","article-title":"Cohesin in cancer: Chromosome segregation and beyond","volume":"14","author":"Losada","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"key20180107190419_b27-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"853","DOI":"10.4161\/cc.5.8.2692","article-title":"Polo-like kinases: A team in control of the division","volume":"5","author":"van de Weerdt","year":"2006","journal-title":"Cell Cycle"},{"key":"key20180107190419_b28-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nrm1401","article-title":"Polo-like kinases and the orchestration of cell division","volume":"5","author":"Barr","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"key":"key20180107190419_b29-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1349-7006.2003.tb01411.x","article-title":"Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers","volume":"94","author":"Takahashi","year":"2003","journal-title":"Cancer Sci"},{"key":"key20180107190419_b30-ijo-49-06-2411","first-page":"2794","article-title":"Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck","volume":"59","author":"Knecht","year":"1999","journal-title":"Cancer Res"},{"key":"key20180107190419_b31-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/sj.bjc.6601610","article-title":"Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma","volume":"90","author":"Weichert","year":"2004","journal-title":"Br J Cancer"},{"key":"key20180107190419_b32-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/sj.onc.1200862","article-title":"Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer","volume":"14","author":"Wolf","year":"1997","journal-title":"Oncogene"},{"key":"key20180107190419_b33-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/2043-9113-1-6","article-title":"RNA interference against polo-like kinase-1 in advanced non-small cell lung cancers","volume":"1","author":"Kawata","year":"2011","journal-title":"J Clin Bioinforma"},{"key":"key20180107190419_b34-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1097\/JTO.0b013e3181d95dd4","article-title":"The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB\/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: Results from an open-label, randomized phase II clinical trial","volume":"5","author":"Sebastian","year":"2010","journal-title":"J Thorac Oncol"},{"key":"key20180107190419_b35-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.cllc.2012.04.003","article-title":"A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer","volume":"14","author":"Ellis","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"key20180107190419_b36-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.tranon.2015.03.010","article-title":"Targeting Polo-Like Kinases: A Promising Therapeutic approach for cancer treatment","volume":"8","author":"Liu","year":"2015","journal-title":"Transl Oncol"},{"key":"key20180107190419_b37-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejca.2011.11.001","article-title":"A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours","volume":"48","author":"Sch\u00f6ffski","year":"2012","journal-title":"Eur J Cancer"},{"key":"key20180107190419_b38-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/cncr.28519","article-title":"An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer","volume":"120","author":"Stadler","year":"2014","journal-title":"Cancer"},{"key":"key20180107190419_b39-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s10637-015-0223-9","article-title":"Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: Safety, pharmacokinetics and activity","volume":"33","author":"Awada","year":"2015","journal-title":"Invest New Drugs"},{"key":"key20180107190419_b40-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00280-015-2860-2","article-title":"A phase I study of volasertib combined with afatinib, in advanced solid tumors","volume":"76","author":"Machiels","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20180107190419_b41-ijo-49-06-2411","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1093\/annonc\/mdv354","article-title":"A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors","volume":"26","author":"de Braud","year":"2015","journal-title":"Ann Oncol"}],"container-title":["International Journal of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ijo.2016.3765\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T19:08:08Z","timestamp":1515352088000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ijo.2016.3765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,10]]},"references-count":41,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,11,10]]},"published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.3892\/ijo.2016.3765"],"URL":"https:\/\/doi.org\/10.3892\/ijo.2016.3765","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,10]]}}}